+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Alcoholic Hepatitis - Pipeline Review, H1 2020

  • ID: 5017472
  • Drug Pipelines
  • March 2020
  • Region: Global
  • 101 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Afimmune Biopharma Ltd
  • Cadila Healthcare Ltd
  • DURECT Corp
  • Gilead Sciences Inc
  • Novartis AG
  • Pattern Therapeutics
  • MORE
Alcoholic Hepatitis - Pipeline Review, H1 2020

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Alcoholic Hepatitis - Pipeline Review, H1 2020, provides an overview of the Alcoholic Hepatitis (Gastrointestinal) pipeline landscape.

Alcoholic hepatitis is an inflammation of the liver. It is typically caused by excessive alcohol consumption over a long period of time. Symptoms include changes in appetite, dry mouth, weight loss, yellowing of the skin or eyes (jaundice), fever and fatigue. Risk factors include alcohol use, obesity and genetic factors. Treatment includes corticosteroids and liver transplant.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Alcoholic Hepatitis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Alcoholic Hepatitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Alcoholic Hepatitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Alcoholic Hepatitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 8, 1 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Alcoholic Hepatitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Alcoholic Hepatitis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Alcoholic Hepatitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Alcoholic Hepatitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Alcoholic Hepatitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Alcoholic Hepatitis (Gastrointestinal)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Alcoholic Hepatitis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Alcoholic Hepatitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Afimmune Biopharma Ltd
  • Cadila Healthcare Ltd
  • DURECT Corp
  • Gilead Sciences Inc
  • Novartis AG
  • Pattern Therapeutics
  • MORE
  • Introduction
  • Alcoholic Hepatitis - Overview
  • Alcoholic Hepatitis - Therapeutics Development
  • Alcoholic Hepatitis - Therapeutics Assessment
  • Alcoholic Hepatitis - Companies Involved in Therapeutics Development
  • Alcoholic Hepatitis - Drug Profiles
  • Alcoholic Hepatitis - Dormant Projects
  • Alcoholic Hepatitis - Discontinued Products
  • Alcoholic Hepatitis - Product Development Milestones
  • Appendix
List of Tables
  • Number of Products under Development for Alcoholic Hepatitis, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Alcoholic Hepatitis - Pipeline by Afimmune Biopharma Ltd, H1 2020
  • Alcoholic Hepatitis - Pipeline by Cadila Healthcare Ltd, H1 2020
  • Alcoholic Hepatitis - Pipeline by DURECT Corp, H1 2020
  • Alcoholic Hepatitis - Pipeline by Generon (Shanghai) Corp Ltd, H1 2020
  • Alcoholic Hepatitis - Pipeline by Gilead Sciences Inc, H1 2020
  • Alcoholic Hepatitis - Pipeline by Intercept Pharmaceuticals Inc, H1 2020
  • Alcoholic Hepatitis - Pipeline by Novartis AG, H1 2020
  • Alcoholic Hepatitis - Pipeline by Pattern Therapeutics, H1 2020
  • Alcoholic Hepatitis - Pipeline by PharmaKing Co Ltd, H1 2020
  • Alcoholic Hepatitis - Dormant Projects, H1 2020
  • Alcoholic Hepatitis - Discontinued Products, H1 2020
List of Figures
  • Number of Products under Development for Alcoholic Hepatitis, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Afimmune Biopharma Ltd
  • Cadila Healthcare Ltd
  • DURECT Corp
  • Generon (Shanghai) Corp Ltd
  • Gilead Sciences Inc
  • Intercept Pharmaceuticals Inc
  • Novartis AG
  • Pattern Therapeutics
  • PharmaKing Co Ltd
  • Rejuvenation Technologies Inc
  • Vectus Biosystems Ltd
  • Verlyx Pharma Inc
  • Virpharm Pharmaceutical Co
Note: Product cover images may vary from those shown
Adroll
adroll